Renal cell carcinoma, VHL-associated
Revision as of 18:40, 25 March 2023 by Warner-admin (talk | contribs) (Text replacement - "|Years of enrollment" to "|Dates of enrollment")
Section editor transclusions Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Belzutifan monotherapy
Regimen
Study | Dates of enrollment | Evidence | |
---|---|---|---|
Jonasch et al. 2021 (MK-6482-004)
|
5/31/2018-3/29/2019 | Phase 2 (RT) |
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article Pubmed NCT03401788